Patritumab Deruxtecan Drug Asset Due Diligence Report 2026

This Patritumab Deruxtecan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Patritumab Deruxtecan can convert its Antibody drug conjugate (ADC) profile and HER3 x Top I biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Patritumab Deruxtecan (query alias: Patritumab Deruxtecan)
Modality / target	Antibody drug conjugate (ADC); HER3 x Top I; HER3 antagonists, TOP1 inhibitors
Highest global status	Phase 3
Originator	Daiichi Sankyo Co., Ltd.
Active developers	Merck Sharp & Dohme LLC, Daiichi Sankyo Co., Ltd., Daiichi Sankyo, Inc.

The MCP disease footprint includes Hormone receptor positive HER2 negative breast cancer, EGFR-mutated non-small Cell Lung Cancer, Non-squamous non-small cell lung cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07060807	Phase 3	Recruiting	1000	Progression Free Survival (PFS)
NCT07701941	Phase 1/2	Not yet recruiting	220	Part 1: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
NCT07286149	Phase 1/2	Recruiting	190	Number of Participants Who Experience a Dose Limiting Toxicity (DLT)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Patritumab Deruxtecan addresses Hormone receptor positive HER2 negative breast cancer, EGFR-mutated non-small Cell Lung Cancer, Non-squamous non-small cell lung cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-10-19	Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs	Phase 3	US$4,000.0M upfront; US$18,000.0M milestones; US$22,000.0M stated total
2020-08-06	Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer	Phase 2	Financial terms not disclosed
2020-07-22	Gustave Roussy collaborates with Daiichi to conduct research studies on DS-1062 for NSCLC and U3-1402 for breast cancer.	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of (Anti-her3 antibody)-drug conjugate and RASG12c inhibitor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

CLDN18.2 assay, cutoff, and intratumoral heterogeneity
Payload-related toxicity and dose intensity
Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO